指南与共识胸部肿瘤

美国镭学会不可切除局部晚期非小细胞肺癌适宜使用标准

American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
指南 / 共识 · JAMA Oncol · 2024-01-01

美国镭学会胸部委员会基于系统文献综述与改良Delphi共识(3–9分)制定不可切除局部晚期非小细胞肺癌的适宜使用标准,推荐预后良好者行同步根治性铂类放化疗(60–70 Gy)后度伐利尤单抗巩固治疗,放疗通常采用调强放疗技术,并对体能或肺功能差者及局部复发者给出分层建议。

要点

  • 预后良好者标准治疗为同步根治性铂类放化疗(60–70 Gy)后度伐利尤单抗巩固(用于未进展者)。
  • 局部晚期肺癌放疗的计划与实施通常应采用调强放疗技术。
  • 体能和/或肺功能差者可选择多种姑息与根治性分割方案。

核心结论

  • 美国镭学会适宜使用标准为多种不可切除局部晚期非小细胞肺癌情形提供循证指导,以优化多学科诊疗。

研究设计与样本

  • 美国镭学会适宜使用标准胸部委员会制定,基于系统文献综述与证据评级,采用改良Delphi共识法(3–9分表示共识程度)。
  • 推荐经美国镭学会适宜使用标准执行委员会审核并经过2周公众评论期后正式批准采纳。

主要发现

  • 预后良好局部晚期非小细胞肺癌的标准治疗为同步根治性铂类放化疗(60–70 Gy)后度伐利尤单抗巩固免疫治疗(用于未进展者)。
  • 局部晚期肺癌放疗的计划与实施通常应采用调强放疗技术。
  • 体能和/或肺功能差者可选择多种姑息与根治性分割方案。
  • 成功初始治疗后的局部复发挽救治疗复杂,可能需要多学科参与并与患者共同决策。

关键数值与推荐

  • 预后良好者:同步根治性铂类放化疗剂量60–70 Gy,随后度伐利尤单抗巩固(未进展者)。
  • 放疗计划与实施通常采用调强放疗技术。
  • 共识采用3–9分范围表示共识程度。

临床怎么用

  • 对预后良好的不可切除局部晚期非小细胞肺癌,按标准治疗行同步根治性铂类放化疗(60–70 Gy)后度伐利尤单抗巩固(未进展者)。
  • 放疗计划与实施通常采用调强放疗技术。
  • 体能和/或肺功能差者可选择姑息或根治性分割方案。
  • 局部复发挽救治疗需多学科参与并与患者共同决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The treatment of locally advanced non-small cell lung cancer (LA-NSCLC) has been informed by more than 5 decades of clinical trials and other relevant literature. However, controversies remain regarding the application of various radiation and systemic therapies in commonly encountered clinical scenarios. OBJECTIVE: To develop case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable LA-NSCLC. EVIDENCE REVIEW: The American Radium Society (ARS) Appropriate Use Criteria (AUC) Thoracic Committee guideline is an evidence-based consensus document assessing various clinical scenarios associated with LA-NSCLC. A systematic review of the literature with evidence ratings was conducted to inform the appropriateness of treatment recommendations by the ARS AUC Thoracic Committee for the management of unresectable LA-NSCLC. FINDINGS: Treatment appropriateness of a variety of LA-NSCLC scenarios was assessed by a consensus-based modified Delphi approach using a range of 3 points to 9 points to denote consensus agreement. Committee recommendations were vetted by the ARS AUC Executive Committee and a 2-week public comment period before official approval and adoption. Standard of care management of good prognosis LA-NSCLC consists of combined concurrent radical (60-70 Gy) platinum-based chemoradiation followed by consolidation durvalumab immunotherapy (for patients without progression). Planning and delivery of locally advanced lung cancer radiotherapy usually should be performed using intensity-modulated radiotherapy techniques. A variety of palliative and radical fractionation schedules are available to treat patients with poor performance and/or pulmonary status. The salvage therapy for a local recurrence after successful primary management is complex and likely requires both multidisciplinary input and shared decision-making with the patient. CONCLUSIONS AND RELEVANCE: Evidence-based guidance on the management of various unresectable LA-NSCLC scenarios is provided by the ARS AUC to optimize multidisciplinary patient care for this challenging patient population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rodrigues G, Higgins KA, Rimner A, et al. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024. PMID: 38602670. doi:10.1001/jamaoncol.2024.0294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。